Localized Administration of Bcar3 siRNA via Nano-Self-Assembly to Treat Idiopathic Pulmonary Fibrosis by Disrupting Macrophage-Fibroblast Crosstalk

References

• Prele CM, Miles T, Pearce DR, et al. Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis. Eur Respir J. 2022;60(5):2101469. doi:10.1183/13993003.01469-2021
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao J, Zhang H, Wang CY. Arginine is a key player in fibroblasts during the course of IPF development. Mol Ther. 2021;29(4):1361–1363. doi:10.1016/j.ymthe.2021.02.023
   PubMed Web of Science ®Google Scholar
• Hu Y, Wang Q, Yu J, et al. Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating beta-catenin signaling. Nat Commun. 2022;13(1):114. doi:10.1038/s41467-021-27684-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Wu GR, et al. MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Sci Adv. 2021;7(1):eabb6075.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Huang T, et al. The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation. Eur Respir J. 2022;60(3):2003697. doi:10.1183/13993003.03697-2020
   PubMed Web of Science ®Google Scholar
• Buechler MB, Fu W, Turley SJ. Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer. Immunity. 2021;54(5):903–915. doi:10.1016/j.immuni.2021.04.021
   PubMed Web of Science ®Google Scholar
• Rao LZ, Wang Y, Zhang L, et al. IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages. Cell Death Differ. 2021;28(4):1270–1283. doi:10.1038/s41418-020-00650-6
   PubMed Web of Science ®Google Scholar
• Prasse A, Pechkovsky DV, Toews GB, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173(7):781–792. doi:10.1164/rccm.200509-1518OC
   PubMed Web of Science ®Google Scholar
• Doroudian M, O’Neill A, Mac Loughlin R, Prina-Mello A, Volkov Y, Donnelly SC. Nanotechnology in pulmonary medicine. Curr Opin Pharmacol. 2021;56:85–92. doi:10.1016/j.coph.2020.11.002
   PubMed Web of Science ®Google Scholar
• Ding L, Tang S, Tang W, et al. Perfluorocarbon nanoemulsions enhance therapeutic siRNA delivery in the treatment of pulmonary fibrosis. Adv Sci. 2022;9(8):e2103676.
   Web of Science ®Google Scholar
• Ghasemzad M, Hashemian SMR, Memarnejadian A, Akbarzadeh I, Hossein-Khannazer N, Vosough M. The nano-based theranostics for respiratory complications of COVID-19. Drug Dev Ind Pharm. 2021;47(9):1353–1361. doi:10.1080/03639045.2021.1994989
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu J, Hu Y, et al. Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition. Theranostics. 2021;11(14):7110–7125. doi:10.7150/thno.61085
   PubMed Web of Science ®Google Scholar
• Pan T, Zhou Q, Miao K, et al. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis. Theranostics. 2021;11(3):1192–1206. doi:10.7150/thno.48152
   PubMed Web of Science ®Google Scholar
• Arras J, Thomas KS, Myers PJ, et al. Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes tumor growth and progression in triple-negative breast cancer. Am J Cancer Res. 2021;11(10):4768–4787.
   PubMed Web of Science ®Google Scholar
• Steenkiste EM, Berndt JD, Pilling C, Simpkins C, Cooper JA. A Cas-BCAR3 co-regulatory circuit controls lamellipodia dynamics. Elife. 2021;10:e67078.
   PubMed Web of Science ®Google Scholar
• Zhang W, Lin Y, Liu X, et al. Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma. J Transl Med. 2018;16(1):363. doi:10.1186/s12967-018-1728-8
   PubMedGoogle Scholar
• Riggins RB, Quilliam LA, Bouton AH. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J Biol Chem. 2003;278(30):28264–28273. doi:10.1074/jbc.M303535200
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers J, Richeldi L, Wilson KC. The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory. Am J Respir Crit Care Med. 2019;200(9):1089–1092. doi:10.1164/rccm.201907-1324ED
   PubMed Web of Science ®Google Scholar
• Mou Y, Wu GR, Wang Q, et al. Macrophage-targeted delivery of siRNA to silence Mecp2 gene expression attenuates pulmonary fibrosis. Bioeng Transl Med. 2022;7(2):e10280. doi:10.1002/btm2.10280
   PubMed Web of Science ®Google Scholar
• Wang Q, Yu J, Hu Y, et al. Indirubin alleviates bleomycin-induced pulmonary fibrosis in mice by suppressing fibroblast to myofibroblast differentiation. Biomed Pharmacother. 2020;131:110715. doi:10.1016/j.biopha.2020.110715
   PubMed Web of Science ®Google Scholar
• Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010;107(5):1864–1869. doi:10.1073/pnas.0910603106
   PubMed Web of Science ®Google Scholar
• Ahangari F, Becker C, Foster DG, et al. Saracatinib, a selective src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis. Am J Respir Crit Care Med. 2022;206(12):1463–1479. doi:10.1164/rccm.202010-3832OC
   PubMed Web of Science ®Google Scholar
• Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76(11):1941–1948. doi:10.1136/annrheumdis-2016-210823
   PubMed Web of Science ®Google Scholar
• Yao Y, Wang Y, Zhang Z, et al. Chop deficiency protects mice against bleomycin-induced pulmonary fibrosis by attenuating M2 macrophage production. Mol Ther. 2016;24(5):915–925. doi:10.1038/mt.2016.36
   PubMed Web of Science ®Google Scholar
• Lv Q, Wang J, Xu C, Huang X, Ruan Z, Dai Y. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3beta/beta-catenin and TGF-beta1/Smad2/3 signaling pathways. Mol Med. 2020;26(1):49. doi:10.1186/s10020-020-00173-3
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Y, Wu G, Xiong W, Gu W, Wang CY. Macrophages: friend or foe in idiopathic pulmonary fibrosis? Respir Res. 2018;19(1):170. doi:10.1186/s12931-018-0864-2
   PubMedGoogle Scholar
• Schuh NR, Guerrero MS, Schrecengost RS, Bouton AH. BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. J Biol Chem. 2010;285(4):2309–2317. doi:10.1074/jbc.M109.046631
   PubMed Web of Science ®Google Scholar
• Hu X, Wang H, Han C, Cao X. Src promotes anti-inflammatory (M2) macrophage generation via the IL-4/STAT6 pathway. Cytokine. 2018;111:209–215. doi:10.1016/j.cyto.2018.08.030
   PubMed Web of Science ®Google Scholar
• Hu M, Che P, Han X, et al. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther. 2014;351(1):87–95. doi:10.1124/jpet.114.216044
   PubMed Web of Science ®Google Scholar
• Cai D, Iyer A, Felekkis KN, et al. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res. 2003;63(20):6802–6808.
   PubMed Web of Science ®Google Scholar
• Fu J, Liu B, Zhang H, et al. The role of cell division control protein 42 in tumor and non-tumor diseases: a systematic review. J Cancer. 2022;13(3):800–814. doi:10.7150/jca.65415
   PubMed Web of Science ®Google Scholar
• Guo J, Canaff L, Rajadurai CV, et al. Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor beta/Smad signaling and associates with favorable breast cancer disease outcomes. Breast Cancer Res. 2014;16(6):476. doi:10.1186/s13058-014-0476-9
   PubMed Web of Science ®Google Scholar
• Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265–280. doi:10.1038/s41576-021-00439-4
   PubMed Web of Science ®Google Scholar
• Kedmi R, Veiga N, Ramishetti S, et al. A modular platform for targeted RNAi therapeutics. Nat Nanotechnol. 2018;13(3):214–219. doi:10.1038/s41565-017-0043-5
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446. doi:10.1038/s41573-019-0017-4
   PubMed Web of Science ®Google Scholar